Format

Send to

Choose Destination
Naunyn Schmiedebergs Arch Pharmacol. 2016 Sep;389(9):931-49. doi: 10.1007/s00210-016-1256-0. Epub 2016 May 13.

Rosemary (Rosmarinus officinalis) as a potential therapeutic plant in metabolic syndrome: a review.

Author information

1
Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
2
Pharmaceutical Research Center, Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. HosseinzadehH@mums.ac.ir.

Abstract

Metabolic syndrome is defined by a constellation of complex coexisting cardiometabolic risk factors such as hyperglycemia, dyslipidemia, inflammation, abdominal obesity, coagulopathies, and hypertension that raise the risk of diabetes mellitus and cardiovascular disease. Recently, there has been an increasing interest in the use of herbs and natural compounds in prevention and treatment of diseases and a large number of published articles have focused on this issue. Rosmarinus officinalis L. or rosemary (Lamiaceae) is a rich source of phenolic phytochemicals having significant anti-oxidant, anti-inflammatory, hypoglycemic, hypolipidemic, hypotensive, anti-atherosclerotic, anti-thrombotic, hepatoprotective, and hypocholesterolemic effects. The purpose of this review is to highlight the interesting pharmacological effects of rosemary, and its active compounds, and the related mechanisms in the management of metabolic syndrome that are documented in in vitro and in vivo studies.

KEYWORDS:

Cardiovascular disease; Diabetes; Metabolic syndrome; Obesity; Rosmarinus officinalis

PMID:
27178264
DOI:
10.1007/s00210-016-1256-0
[Indexed for MEDLINE]

Publication type, MeSH terms, Substances

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center